QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nkgen-biotech-receives-fda-expanded-access-approval-to-treat-multiple-neurodegenerative-diseases-with-troculeucel

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit wi...

 nkgen-biotech-announces-chairman--ceo-paul-y-song-md-personally-invests-265m-cash-to-accelerate-phase-2-clinical-trial-and-fulfill-financial-reporting-obligations

New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 ...

 nkgen-biotech-selected-as-stalking-horse-bidder-for-nkmax-nkgen-proposal-included-up-to-18m-in-committed-funding

Upon closing, the transaction would secure global IP rights for NKGen.NKGen and its partners can begin to commercialize trocule...

 nkgen-biotech-receives-notifications-from-nasdaq-related-to-delayed-quarterly-report-and-decision-of-the-nasdaq-hearings-panel-the-company-does-not-intend-to-appeal-the-decision-letter-at-this-time-and-intends-to-deliver-an-updated-plan-of-compliance-to-the-panel-no-later-than-january-7-2025

NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), today announced it received a notice (the "No...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION